Skip to main content

Table 4 Comparison of efficacy and the adverse events between the two treatments in hemodynamically and anatomically massive PE subgroups

From: Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial

 

Hemodynamically massive PE

 

Anatomically massive PE

 
 

UK 12 h

(n = 20)

UK 2 h

(n = 20)

p

UK 12 h

(n = 50)

UK 2 h

(n = 39)

p

Efficacy

      

Pulmonary artery obstruction score by CTPA*

Baseline

16.1 ± 7.7

17.3 ± 10.5

0.670

13.7 ± 7.2

14.7 ± 7.6

0.523

24 -hour

13.1 ± 7.7

13.5 ± 11.7

0.899

10.5 ± 6.9

10.9 ± 8.1

0.783

14- day

6.9 ± 7.3

5.2 ± 9.8

0.527

4.5 ± 5.2

3.7 ± 4.6

0.452

Adverse events

      

Death

0 (0)

2 (10.0)

0.487

1(2)****

0(0)

1.000

Due to PE

0(0)

1 (5.0)**

 

0 (0)

0(0)

 

Due to other reason

0(0)

1 (5.0)***

 

0 (0)

0(0)

 

Due to Bleeding

0 (0)

0(0)

 

0 (0)

0(0)

 

Recurrent PE

0 (0)

0(0)

 

1(2)

0(0)

 

Bleeding complications

3(15)

3(15)

1.000

7(14)

5(13)

1.000

Major bleeding

1 (5.0)

3 (15.0)

0.605

3 (6)

3 (7.7)

1.000

Fatal bleeding

0 (0)

0(0)

 

0(0)

0(0)

 

Other

1 (5.0)

3 (15.0)

 

3(6)

3 (7.7)

 

Minor bleeding

2(10.0)

0(0.0)

0.487

4(8)

2(5.1)

0.692

  1. * CT pulmonary angiographic assessment, Data presented are number (%) of patients.**The patient died due to the severity of PE. *** The patient died due to the commodities of acute myocardial infarction. **** The patient died due to recurrent PE.